Neurotech Pharmaceuticals, Inc.

Neurotech Pharmaceuticals, Inc. company information, Employees & Contact Information

Neurotech Pharmaceuticals, Inc. is a private biotech company focused on developing transformative therapies for chronic eye diseases. The core platform technology, Encapsulated Cell Therapy (ECT) is a first in class, drug delivery platform designed to slow the progression of idiopathic Macular Telangiectasia type 2 in adults and other chronic eye diseases.

Company Details

Employees
126
Address
900 Highland Corporate Drive, Building 1, Suite 101, Building 1
Phone
+1 401 333 3880
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Technician jobs.
HQ
Cumberland, RI
Looking for a particular Neurotech Pharmaceuticals, Inc. employee's phone or email?

Neurotech Pharmaceuticals, Inc. Questions

News

Neurotech Appoints Beth Marsh as Chief Commercial Officer - Business Wire

Neurotech Appoints Beth Marsh as Chief Commercial Officer Business Wire

Neurotech Granted Permanent J-Code (J3403) for ENCELTO™ (revakinagene taroretcel-lwey), Effective October 1, 2025 - Yahoo Finance

Neurotech Granted Permanent J-Code (J3403) for ENCELTO™ (revakinagene taroretcel-lwey), Effective October 1, 2025 Yahoo Finance

Neurotech Pharmaceuticals, Inc. Granted Fast Track Designation from the U.S. FDA for the Treatment of Macular Telangiectasia type 2 - PR Newswire

Neurotech Pharmaceuticals, Inc. Granted Fast Track Designation from the U.S. FDA for the Treatment of Macular Telangiectasia type 2 PR Newswire

Neurotech Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors - Business Wire

Neurotech Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors Business Wire

Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel) - Yahoo Finance

Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel) Yahoo Finance

Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire

Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) Business Wire

Alex Gorsky Joins Neurotech’s Board as Lead Director - Business Wire

Alex Gorsky Joins Neurotech’s Board as Lead Director Business Wire

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) Business Wire

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer - Business Wire

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer Business Wire

Neurotech Pharmaceuticals, Inc. Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2 - Business Wire

Neurotech Pharmaceuticals, Inc. Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2 Business Wire

Top Neurotech Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant